University of California San Francisco
Give to UCSFResearchers at UCSF have identified specific gut microbes associated with MS in human patients, showing that these microbes take part in regulating immune responses in mouse models of the disease.
Research team led by University of California scientists has used a modified version of the gene-editing technique CRISPR to find enhancers by prompting them into action.
A study headed by UCSF researchers fuels the probiotics debate by finding that there is no clear evidence that a supplement of the “friendly” bacteria strain of lactobacillus prevents eczema.
A virus hiding quietly in the gut may trigger the onset of a severe complication known as graft-versus-host disease (GvHD) in patients who receive bone marrow transplants.
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study.
Immune cells in the brain trigger overeating and weight gain in response to diets rich in fat, according to a new study in mice led by researchers from UCSF and the UW Medical Center.
In experiments in mice, UC San Francisco researchers have discovered that regulatory T cells, directly trigger stem cells in the skin to promote healthy hair growth.
How T cells feel out intruders rapidly and reliably enough to nip infections and other threats in the bud has remained a mystery to researchers.
UCSF researchers have helped to identify the three evolutionary steps the polio virus used to evolve from harmless vaccine into a regional menace. With the new knowledge, they have developed a new polio vaccine that should be unable to escape and cause outbreaks.
New research has found that successful cancer immunotherapy appears to depend on whether the treatment can trigger a system-wide immune response, rather than just a local response within the tumor itself.
UC San Francisco scientists have formed an innovative research alliance with three global pharmaceutical companies.
In findings that show the effectiveness of a new strategy for treating multiple sclerosis, researchers are reporting positive results from three large, international, multicenter Phase III clinical trials of the investigational drug ocrelizumab in both relapsing multiple sclerosis and primary progressive multiple sclerosis.
UCSF-led research team identified the rare genetic mutation responsible for a unique case of severe combined immunodeficiency, a deadly immune system disorder also known as “boy in the bubble” disease.